About those Pfizer and Moderna Phase 3 clinical trials
Follow ups indicate increased risk of hospitalization of those injected.
For those that have not yet seen the analysis of the Pfizer clinical trials by the Canadian Covid Care Alliance from last November (before the FDA’s EUA and roll-out of injections), you can check it out here - see especially, pages 11 and 12 for the exchange of a reduction of 4% in CoVID-19 cases for an extra 16% of adverse events (and an extra six all cause mortalities in the 22,000 aside injected group v placebo group).
The COVID-19 Inoculations - More Harm Than Good FINAL Video & Print - MoreHarm.pdf | DocDroid
Here is a critique of the Moderna clinical trials
Moderna's Non-clinical Summary for Spikevax - Evidence of Scientific and Regulatory Fraud (trialsitenews.com)
So, what about a follow up to the injected group of 22,000 or so clinical trial participants?
h/t Brownstone Institute
check this out
Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials by Joseph Fraiman, Juan Erviti, Mark Jones, Sander Greenland, Patrick Whelan, Robert M. Kaplan, Peter Doshi :: SSRN
“Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9). The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively).”
An increase of 10.1 per 10k for Pfizer, 15.1 per 10k for Moderna and a combined 12.5 per 10k OF SERIOUS ADVERSE EVENTS ABOVE BASELINE.
These increased serious adverse events EXCEEDED THE RISK REDUCTIONS FOR HOSPITALIZATIONS FROM COVID19 BY BETWEEN 2 (PFIZER) AND 6 (MODERNA) PER 10,000.
So now you know. The clinical trial participants in the injected group were generally healthier than the general population and suffered more. This was before boosters.
https://expose-news.com/2022/09/02/trial-data-higher-serious-events-among-vaccinated/
https://www.hartgroup.org/first-finding-from-pfizer-trials/
"There were 165 people who started with negative antibodies but became positive during the trial in the placebo arm. That is a pretty close match to the 162 who were positive by PCR testing. However there were 75 in the vaccine arm, far more than the 8 claimed by PCR testing. That would mean that treatment only reduced the risk of infection by about half the 95% claimed.
Only 40% of people who had been given Moderna produced N-antibodies after symptomatic, PCR positive infection. Moderna and Pfizer have products that are very similar in terms of mechanism of action, so it is not unreasonable to assume that a similar issue would be seen with Pfizer.
If that is the case, then the 75 figure would only be a fraction of the people in the treatment arm who had been infected. Assuming the 40% figure holds, that would mean that there was no efficacy from Pfizer vaccination against risk of infection when measuring the entire period from first needle to end of the trial. "